Immunotherapy agents show great promise and are currently used to treat a growing range of cancers. However, emerging evidence from randomized trials and clinical practice demonstrate highly variable patterns of toxicity and treatment response that can lead to severe immune-related adverse events. The complex interplay between tumor response, immune-induced organ toxicity and immune system activation make a comprehensive assessment of treatment response extremely difficult.